Prestige BioPharma Limited (950210.KS)

KRW 15050.0

(-4.57%)

Net Income Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual net income in 2023 was -32.92 Billion KRW , down -287.38% from previous year.
  • Prestige BioPharma Limited's latest quarterly net income in 2023 Q4 was -9.28 Billion KRW , down -541.33% from previous quarter.
  • Prestige BioPharma Limited reported an annual net income of 17.56 Billion KRW in 2022, up 108.31% from previous year.
  • Prestige BioPharma Limited reported an annual net income of -211.45 Billion KRW in 2021, down -2760.94% from previous year.
  • Prestige BioPharma Limited reported a quarterly net income of -1.44 Billion KRW for 2023 Q3, up 88.89% from previous quarter.
  • Prestige BioPharma Limited reported a quarterly net income of -9.28 Billion KRW for 2023 Q4, down -541.33% from previous quarter.

Annual Net Income Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Net Income of Prestige BioPharma Limited (2023 - 2017)

Year Net Income Net Income Growth
2023 -32.92 Billion KRW -287.38%
2022 17.56 Billion KRW 108.31%
2021 -211.45 Billion KRW -2760.94%
2020 -7.39 Billion KRW 50.72%
2019 -14.99 Billion KRW -936.06%
2018 -1.44 Billion KRW 35.04%
2017 -2.22 Billion KRW 0.0%

Peer Net Income Comparison of Prestige BioPharma Limited

Name Net Income Net Income Difference
ORIENT BIO Inc. 12.87 Billion KRW 355.777%
Green Cross Holdings Corporation -54.13 Billion KRW 39.188%
Green Cross Holdings Corporation -26.63 Billion KRW -23.616%
Pharmicell Co., Ltd. 3.57 Billion KRW 1020.106%
Green Cross Corporation -26.63 Billion KRW -23.616%
GeneOne Life Science, Inc. -77.76 Billion KRW 57.667%
Celltrion, Inc. 535.64 Billion KRW 106.146%
Samsung Biologics Co.,Ltd. 857.69 Billion KRW 103.838%
SK bioscience Co.,Ltd. 22.31 Billion KRW 247.512%
SK Biopharmaceuticals Co., Ltd. -32.88 Billion KRW -0.117%